The availability of TNF-á inhibitors fueled a tremendous year-on-year increase in the ankylosing
spondylitis (AS) market from 2006 to 2007, and we expect signifi cant growth to continue over the
next ten years. Although these agents may establish themselves as the gold-standard treatment for
AS, emerging agents can still capitalize on the need for lower-priced, convenient, and effi cacious
agents. Thus, the AS market continues to represent an opportunity for companies.
Get the Answers You Need to Shape Your Strategy
AS is a chronic, debilitating disease that signifi cantly affects patients’ quality of life. How many
people in the United States and Europe have AS? How will this population grow over the next
ten years? What are the issues surrounding the diagnosis of AS?
Diagnosis of AS is often delayed for years after the onset of symptoms. What are the symptoms of AS? How is the disease diagnosed? What are the risk factors for the disease?
The availability of TNF-á inhibitors has changed the approach to AS treatment. What are rheumatologists’ preferred treatments for AS? How robust is the pipeline of developmental AS agents? How will these agents fi t into the treatment algorithm for AS?
The AS market has experienced strong growth over the past few years. What was the size of the 2007 AS market? What drugs are the market leaders? Will emerging agents be able to establish themselves in the AS market?
Scope
Primary research: survey of U.S. rheumatologists.
Overview of AS: etiology, symptoms, and diagnosis.
Current treatments: nonsteroidal anti-infl ammatory agents, disease-modifying antirheumatic drugs, TNF-á inhibitors, corticosteroids, and bisphosphonates.
Epidemiology: prevalent cases of AS in the United States, France, Germany, Italy, Spain, and the United Kingdom.
(0 items)
